Psychedelic Study Links Adverse Trips to Lower Well-Being

Psychedelic Safety: Why Care Should Continue After the Trip

A psychedelic experience can end long before questions about its effects are resolved. Someone may leave a session feeling hopeful, unsettled, or both. Understanding what happens afterward is increasingly important as researchers investigate these substances and public interest expands.

A new study in Psychiatry Research examines adverse reactions to psychedelics in everyday, non-clinical settings and their associations with current mental health and well-being.¹ Its findings suggest that reports of difficulties during intoxication often accompany reports of similar difficulties afterward.

The encouraging implication is that safety can become more specific and measurable. Rather than treating an experience as successful simply because the immediate effects have passed, researchers and care providers can investigate how people function afterward and which forms of support might help.

What the Psychedelic Safety Study Examined

Led by Jaime Rojas-Hernández and colleagues, the research used an online survey of 1,022 participants. Of these, 750 had used psychedelics, while 272 had not. Analyses of psychedelic use and adverse reactions were restricted to lifetime users, with some variation in sample size because of missing responses.

Participants described substance use, motivations, surroundings, companions, and adverse reactions during and after intoxication. The researchers also assessed current psychological symptoms and well-being. This provided a broad picture of experiences outside clinical trials, where substance identity, dosing, screening, and supervision can be less standardized.

The survey grouped pharmacologically different substances, including classic psychedelics, MDMA, and ketamine. Its overall findings therefore should not be interpreted as a single safety profile shared by every substance.

Why Aftercare Deserves More Attention

The central finding was an association between acute and delayed adverse reactions. Participants reporting anxiety, paranoia, or other difficulties during intoxication often also reported the same or related problems afterward. Most adverse-reaction categories were associated with greater current psychological symptoms and lower well-being.

This does not mean an anxious session necessarily produces lasting harm. The researchers did not observe participants before use and follow them forward. They collected retrospective accounts and current psychological measurements at one time, leaving the direction of the relationship unresolved.

Nevertheless, the pattern supports a useful research question: could structured follow-up identify difficulties that would otherwise remain invisible? A session-level safety assessment and a longer-term assessment answer different questions. Whether someone needed immediate assistance is distinct from whether they later struggled with sleep, relationships, or daily responsibilities.

A separate 2026 study of post-psychedelic PTSD symptoms reinforces the relevance of persistent distress. It surveyed 243 people specifically recruited because they had experienced a difficult or traumatic psychedelic episode with continuing aftereffects. Some reported substantial PTSD symptoms, but this selected sample cannot establish how frequently such problems occur among all users. Symptoms were assessed through self-report rather than diagnostic interviews.

Integration Should Leave Room for Clinical Assessment

Integration commonly refers to making sense of an experience and connecting it with everyday life. That can be a useful framework, but it should leave room for recognizing distress that requires clinical assessment. Persistent impairment should not automatically be described as personal growth or a necessary stage of healing.

A practical direction for future care models would combine opportunities to discuss experiences with clear routes to qualified help. The present study did not test whether integration services or follow-up appointments reduce harm, so their effectiveness remains a question for prospective research.

Supportive Settings Are More Than a Label

The survey also found associations involving motivations, locations, and companions. Retreats and shamanic settings appeared disproportionately in some adverse-reaction subgroups, including patterns involving DMT.

This is not evidence that retreats or traditional practices caused adverse reactions. People seeking these settings may differ in psychological vulnerability, expectations, substances used, and reasons for attending. The study could not connect each reaction with a particular episode or establish the incidence of harm across all retreat participants.

The broader insight is that setting should be evaluated through concrete practices. A welcoming environment and a reassuring description reveal little about screening, staff competence, emergency response, or support after departure. Future studies could measure those elements individually instead of treating every guided experience as equivalent.

MyCannabis recently explored why the psychedelic experience may be part of the medicine. The safety question adds another dimension: if experience and context potentially contribute to benefit, they also deserve careful evaluation when outcomes are difficult.

What Cannabis Co-Use Findings Can Actually Tell Us

Cannabis, alcohol, and caffeine were the substances most frequently reported in combination with psychedelics in the new survey. However, the researchers could not tie a specific adverse reaction to a specific combination, dose, or episode. Reporting both cannabis co-use and a reaction does not establish that cannabis caused or prevented it.

A September 2026 study of age and cannabis co-use illustrates the uncertainty. Among 365 current psilocybin users, cannabis co-use was associated with greater perceived improvements in several outcomes, including quality of life and anxiety. That study was also retrospective and cannot demonstrate that combining substances improves treatment or safety.

Together, these findings point toward better questions rather than a recommendation to combine drugs. Future research needs to distinguish simultaneous use from broader consumption patterns and record timing, amount, product composition, and baseline mental health.

There is also no basis in the attached study for presenting retail CBD as protection against difficult psychedelic experiences. Product-selection guidance cannot resolve that clinical question.

Why Difficult Experiences Need Better Definitions

The survey used broad reaction categories without consistently measuring severity, duration, functional impairment, or need for medical intervention. That places very different experiences within the same analytical framework.

A brief period of nausea and weeks of disabling anxiety should not carry the same clinical weight. Future research can improve on this by recording:

• When symptoms began and how long they lasted.
• How symptoms affected sleep, work, and relationships.
• Whether professional assessment or treatment was needed.

Vomiting illustrates this measurement challenge. Unlike most acute adverse reactions, it was associated with lower current psychological symptoms and higher well-being. The authors discuss whether ceremonial interpretations of purging might help explain this pattern, but they did not measure those interpretations. The finding does not show that vomiting is therapeutic.

Similarly, the absence of a significant microdosing difference does not prove microdosing is harmless. A null result in this survey cannot establish safety across doses, products, populations, or repeated use.

Better Safety Evidence Can Strengthen Psychedelic Medicine

The study also observed associations between several classic psychedelics and more favorable current psychological indicators. These findings cannot prove benefit, just as its adverse-reaction findings cannot prove harm. Existing vulnerabilities, expectations, and selective recall may influence both.

There are credible reasons to continue investigating therapeutic potential. In a June 2026 overview of psychedelic mental health research, CAMH describes ongoing work on psilocybin for depression, alcohol use disorder, and other conditions. Such clinical research provides opportunities to investigate outcomes with defined protocols and monitoring.

MyCannabis coverage of psychedelics and inflammation research highlights a related lesson: promising findings become more useful when researchers identify the people, conditions, and measurements to which they apply.

The next step is prospective research that measures mental health before exposure, records individual sessions, and follows outcomes over time. That would help distinguish pre-existing difficulties from newly emerging symptoms and test whether specific support practices improve recovery.

Defensible optimism rests on that progress. Better safety evidence can help psychedelic medicine develop around measurable benefit, honest reporting, and care that continues beyond the immediate experience.

References:

¹ Rojas-Hernández, J., Borkel, L. F., Santana del Pino, Á., Quintana-Hernández, D. J., & Henríquez-Hernández, L. A. (2026). Adverse reactions to psychedelics in naturalistic settings are associated with current psychopathology and well-being: A correlational study. Psychiatry Research. Advance online publication. https://doi.org/10.1016/j.psychres.2026.117516